Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer.
코호트
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
36 patients with initially unresectable metastatic GC.
I · Intervention 중재 / 시술
combination treatment with ICIs and chemotherapy, 11 of whom underwent CS
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Overall 2-year survival was 90.0% for those who underwent CS. [CONCLUSION] CS following combination treatment with ICI and chemotherapy may be promising for initially unresectable metastatic GC.
OpenAlex 토픽 ·
Gastric Cancer Management and Outcomes
Gastrointestinal Tumor Research and Treatment
Cancer Immunotherapy and Biomarkers
[AIM] Conversion surgery (CS) for unresectable advanced gastric cancer (GC; clinical stage IVb) has increased in recent years owing to advances in drug therapy.
- 연구 설계 cohort study
APA
Masaaki Nishi, Yuma Wada, et al. (2026). Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer.. World journal of surgery. https://doi.org/10.1002/wjs.70372
MLA
Masaaki Nishi, et al.. "Conversion Surgery Following Combination Treatment With Immune Checkpoint Inhibitors and Chemotherapy for Initially Unresectable Gastric Cancer.." World journal of surgery, 2026.
PMID
41989150
Abstract
[AIM] Conversion surgery (CS) for unresectable advanced gastric cancer (GC; clinical stage IVb) has increased in recent years owing to advances in drug therapy. However, little is known about CS following combination treatment with immune checkpoint inhibitors (ICIs) and chemotherapy.
[METHODS] We conducted a retrospective cohort study of patients initially unresectable metastatic GC. We treated 36 patients with initially unresectable metastatic GC. Thirty-four patients received combination treatment with ICIs and chemotherapy, 11 of whom underwent CS. We evaluated their short-term and long-term surgical outcomes.
[RESULTS] Among patients who underwent CS, six were male and five female, and the median (interquartile range) age was 71 (47-75) years. All patients started first-line therapy with S-1 plus oxaliplatin combined with nivolumab, and two patients underwent surgery after second-line treatment with ramucirumab and nanoparticle albumin-bound paclitaxel. There were four open, two laparoscopic, and five robotic surgeries. The median operative time was 348 (321-354) minutes, blood loss was 16 (10-30) mL, and number of retrieved lymph nodes was 38 (27-44); there were no cases of conversion to laparotomy. R0 resection was achieved in all patients. And postoperative pathology was complete response; three patients, ypStage I; four patients, II; three patient, III; zero patient IV; one patient. ICI and chemotherapy efficacy was Grade 1 in four patients, Grade 2 in two patients, and Grade 3 in five patients. Overall 2-year survival was 90.0% for those who underwent CS.
[CONCLUSION] CS following combination treatment with ICI and chemotherapy may be promising for initially unresectable metastatic GC.
[METHODS] We conducted a retrospective cohort study of patients initially unresectable metastatic GC. We treated 36 patients with initially unresectable metastatic GC. Thirty-four patients received combination treatment with ICIs and chemotherapy, 11 of whom underwent CS. We evaluated their short-term and long-term surgical outcomes.
[RESULTS] Among patients who underwent CS, six were male and five female, and the median (interquartile range) age was 71 (47-75) years. All patients started first-line therapy with S-1 plus oxaliplatin combined with nivolumab, and two patients underwent surgery after second-line treatment with ramucirumab and nanoparticle albumin-bound paclitaxel. There were four open, two laparoscopic, and five robotic surgeries. The median operative time was 348 (321-354) minutes, blood loss was 16 (10-30) mL, and number of retrieved lymph nodes was 38 (27-44); there were no cases of conversion to laparotomy. R0 resection was achieved in all patients. And postoperative pathology was complete response; three patients, ypStage I; four patients, II; three patient, III; zero patient IV; one patient. ICI and chemotherapy efficacy was Grade 1 in four patients, Grade 2 in two patients, and Grade 3 in five patients. Overall 2-year survival was 90.0% for those who underwent CS.
[CONCLUSION] CS following combination treatment with ICI and chemotherapy may be promising for initially unresectable metastatic GC.